USFDA Clearance For Pre Approval Inspection At Ahmedabad Site

21 Apr 2026 CW Team

The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI.

The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting.

Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.

The company has received the Establishment Inspection Report and an approval letter from the United States Food and Drug Administration (USFDA) following a Pre-Approval Inspection at its special economic zone (SEZ) oncology injectable manufacturing facility in SEZ1, Ahmedabad. The clearance relates to a new isolator injectable line and was disclosed in a filing dated 16 April, 2026. The inspection took place from fourth to 13th November, 2025 and resulted in documentation that the company said it had received. The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI. The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting. Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.

Infrastructure Urban

30 May 2026

Panasonic Showcases Connected Display Solutions

Panasonic Life Solutions India showcased its integrated display, projection, broadcast and communication technologies at Panasonic Tech Summit 2026 in New Delhi. Hosted through its System Solutions Division, the two-day event highlighted connected technology solutions for education, healthcare, retail, transportation, corporate offices and entertainment.The summit, themed ‘Turning Technology into Value’, featured experience-led zones covering QSR, retail, transit, corporate offices, healthcare, education, security, projection, home theatre and professional displays. Panasonic also introduc..

Infrastructure Transport

30 May 2026

Kapsch to Deliver India’s First C-ITS Project

"Kapsch TrafficCom will deliver India’s first Cooperative Intelligent Transport Systems project on a key expressway near New Delhi. The project will be implemented with Superwave Communication And Infrasolution Limited to demonstrate how connected mobility can improve road safety and traffic efficiency.The pilot will use real-time connectivity and AI-enabled situational awareness to support road users, especially in high-risk areas such as temporary work zones. Drivers will receive alerts on roadworks, maintenance vehicles, hazardous locations, traffic queues and temporary virtual signage di..

Infrastructure Urban

30 May 2026

Eurobond Net Profit Rises 44 Per Cent

Euro Panel Products, the parent company of Eurobond, reported a 44.13 per cent year-on-year rise in net profit for FY25–26. The company’s revenue from operations grew 18.91 per cent to Rs 503.20 crore, compared to Rs 423.18 crore in the previous financial year.The company’s full-year EBITDA stood at Rs 56.67 crore, marking a 31.82 per cent increase. Profit after tax rose to Rs 26.56 crore, while net worth increased 20.15 per cent to Rs 160.07 crore. Earnings per share for the year stood at Rs 10.84.Divyam Rajesh Shah, Whole Time Director and CFO, Euro Panel Products, said the company’s..